Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection

Lin, Qingqing; Zhu, Li; Ni, Zuowei; Meng, Haitao; You, Liangshun

doi:10.1016/j.jmii.2020.03.015

Cited by 93 publications

(94 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In most SARS patients, B cell and nAB responses were relatively short lived (1-2 years) and prone to antigen escape, raising the possibility of re-infection. In contrast, T cell memory in survivors was long-lived (>6-17 years) (4)(5)(6)(7)19). It is well-known that T cells can engage antigen epitopes that are not targeted by B cells, including those derived from intracellular proteins, to provide broader protection which the virus can less easily circumvent through mutation (6).…”

Section: The Case For T Cellsmentioning

confidence: 99%

An Effective COVID-19 Vaccine Needs to Engage T Cells

Sauer¹,

Harris²

2020

Front. Immunol.

View full text Add to dashboard Cite

Section: The Case For T Cellsmentioning

confidence: 99%

An Effective COVID-19 Vaccine Needs to Engage T Cells

Sauer¹,

Harris²

2020

Front. Immunol.

View full text Add to dashboard Cite

“…39 Neutralizing antibodies are found to be present in SARS patients up to 2 years following recovery. 40…”

Section: Immune Response Mechanismmentioning

confidence: 99%

Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma

Lindholm

Ramsey

Kwaan

2020

Semin Thromb Hemost

View full text Add to dashboard Cite

In the ongoing pandemic of coronavirus disease 2019 (COVID-19), the novel virus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is infecting a naïve population. The innate immunity of the infected patient is unable to mount an effective defense, resulting in a severe illness with substantial morbidity and mortality. As most treatment modalities including antivirals and anti-inflammatory agents are mostly ineffective, an immunological approach is needed. The mechanism of innate immunity to this viral illness is not fully understood. Passive immunity becomes an important avenue for the management of these patients. In this article, the immune responses of COVID-19 patients are reviewed. As SARS-CoV-2 has many characteristics in common with two other viruses, SARS-CoV that cause severe acute respiratory syndrome (SARS) and MERS-CoV (Middle East respiratory syndrome coronavirus) that causes Middle East respiratory syndrome (MERS), the experiences learned from the use of passive immunity in treatment can be applied to COVID-19. The immune response includes the appearance of immunoglobulin M followed by immunoglobulin G and neutralizing antibodies. Convalescent plasma obtained from patients recovered from the illness with high titers of neutralizing antibodies was successful in treating many COVID-19 patients. The factors that determine responses as compared with those seen in SARS and MERS are also reviewed. As there are no approved vaccines against all three viruses, it remains a challenge in the ongoing development for an effective vaccine for COVID-19.

show abstract

“…9 It is, however, probable that any immune response detectable based on antibody production will offer at least some protection against reinfection for some months after primary infection. 10 The suggestion that SARS-CoV-2 may trigger at least short-term protective immunity, similar to SARS-CoV, 8 was supported by Bao et al, 11 in a study showing that clinically significant reinfection did not occur in rhesus macaques rechallenged with SARS-CoV-2. Based on recent evidence for SARS-CoV-2, the timing of detection of IgA and IgM classes earlier, and IgG later, 4,7 along with RT-PCR, could allow for the determination of prior exposure to COVID-19 and probability of continued viral shedding in the nasopharynx, and possibly other specimens (e.g., sputum and stool).…”

mentioning

confidence: 96%

“…4,7 Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) detectable by RT-PCR generally disappears within a few weeks, whereas IgG and neutralizing antibodies persisted longer (months to years) with the original SARS of 2002-2003 (SARS-CoV) and other coronaviral infections. 8 Based on very limited evidence, certain individuals appear to develop high titers of neutralizing antibodies against SARS-CoV-2, whereas others do not. 9 It is, however, probable that any immune response detectable based on antibody production will offer at least some protection against reinfection for some months after primary infection.…”

mentioning

confidence: 99%

COVID-19 Serosurveillance May Facilitate Return-to-Work Decisions

Kršák

Johnson

Poeschla

2020

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Public health measures are needed to resolve the novel coronavirus disease (COVID-19) pandemic, although a looming economic fallout merits close attention. Early safe reintroduction of immune individuals into the workforce may be essential to protecting the economic welfare of communities. Reverse transcriptase-polymerase chain reaction testing, our primary diagnostic tool to date, has sensitivity and timing concerns, owing to sampling/handling errors, as well as a complex virus-host interaction. Reverse transcriptase-polymerase chain reaction assays do not establish immune status once the virus has been cleared. Targeted serosurveillance for the determination of individuals' potential for transmissibility, particularly if paired with direct pathogen testing, may aid in "cleared for business" decision-making.

show abstract

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection

Cited by 93 publications

References 4 publications

An Effective COVID-19 Vaccine Needs to Engage T Cells

An Effective COVID-19 Vaccine Needs to Engage T Cells

Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma

COVID-19 Serosurveillance May Facilitate Return-to-Work Decisions

Contact Info

Product

Resources

About